What is Leerink Partnrs’ Forecast for FATE Q1 Earnings?
Fate Therapeutics, Inc. (NASDAQ:FATE – Free Report) – Analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for shares of Fate Therapeutics in a report released on Thursday, February 13th. Leerink Partnrs analyst D. Graybosch anticipates that the biopharmaceutical company will post earnings per share of ($0.46) for the quarter. The […]
Fate Therapeutics, Inc. (NASDAQ:FATE – Free Report) – Analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for shares of Fate Therapeutics in a report released on Thursday, February 13th. Leerink Partnrs analyst D. Graybosch anticipates that the biopharmaceutical company will post earnings per share of ($0.46) for the quarter. The […]
